Search Results 171-180 of 17415 for Mmol

1. A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma - Mayo Clinic

   Elevated baseline lactate level > ULN (2.3 mmol/L). Any of the following recent prior anti-myeloma therapy: Alkylators (e.g., melaphalan, cyclophosphamide) ...

2. A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) - Mayo Clinic

   Hemoglobin ≥ 8.0 g/dL (4.96 mmol/L);; Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/minute (≤ Grade 1); ...

3. Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation - Mayo Clinic

   2.0 mmol/L (< 8.0 mg/dL) * Hypocalcemia defined by calcium below the normal range (a single value below the normal range does not necessarily constitute ...

4. A Study of Levosimendan in Pulmonary Hypertension (PH) with Heart Failure (HF) and Preserved Left Ventricular Ejection Fraction (pEF) Patients - Mayo Clinic

   Serum potassium < 3.0 mmol/L or > 5.5 mmol/L at baseline that is unresponsive to management . Participating Mayo Clinic locations. Study statuses change ...

5. Midodrine Hydrochloride in Early Sepsis - Clinical Trials

   Lactate more than 8 mmol/L. Midodrine use as a home medication. Known allergy to midodrine. Fludrocortisone acetate is a current home medication ...

6. Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis - Mayo Clinic

   ... mmol/L); red blood cell transfusion allowed up to 7 day prior to registration (within 28 days prior to registration) (NOTE: Growth factor support ...

7. Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET - Mayo Clinic

   Hyperkaleamia > 6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study enrolment. Any patient receiving treatment with short-acting octreotide ...

8. An Observational Study of Patients with Primary Hyperoxaluria Type 1 - Mayo Clinic

   Diagnosis of PH1, confirmed by genotyping for mutations in the AGXT gene. 3. Urine oxalate excretion ≥0.7 mmol per 1.73 m2 body surface area (BSA) in. 24 ...

9. Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer - Mayo Clinic

   Serum potassium ≥ 3.5 mmol/L;; Fasting glucose ≤ 150 mg/dL (8.3 mmol/L) and hemoglobin A1c ≤ 7.5% (58 mmol/mol). Ability to comply with the study protocol ...

10. A Study to Evaluate Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery - Mayo Clinic

    ... mmol/mL) with all previous antidiabetic medication discontinued for at least 6 months before screening. Body mass index (BMI) ≤ 40kg/m2. Willingness to ...